Fig. 5.

CD73 inhibitor AB680 potentiates therapeutic efficacy of anti-PD-1 immunotherapy in murine iCCAs (A) Schematic representation of the schedule for anti-PD-1, CD73 inhibitor AB680, or combination therapy in AKT/NICD-induced murine iCCA model. (B) Body weight of tumor-bearing mice treated with vehicle + 10 mg/kg IgG, 10 mg/kg anti-PD-1, 10 mg/kg AB680, or the combination therapy. (C) Liver images from spontaneous iCCA models that received the indicated treatments (6 mice per group) at the indicated endpoint. (D) Representative IHC staining images for CK19 of liver sections from AKT/NICD-driven murine iCCAs from indicted groups. (E) Statistical analysis of liver weight to body weight ratios (LW/BW) and tumor nodule numbers in AKT-NICD injected mice *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001